NCT02583373 - Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions

PneumoniaPneumococcal Infections

Interventions

DRUG

CAL02 Low-dose

Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion

DRUG

CAL02 High-dose

Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion

DRUG

Placebo

Placebo administered administered 2 times (24 hours apart) as i.v. infusion

Trial Locations (10)

St Luc University Hospital, Brussels

University Hospital Brussels, Brussels

Clinique St Pierre, Ottignies

CHU Jean Minjoz, Besançon

CHD Les Oudairies, La Roche-sur-Yon

Hôpital Mignot, Le Chesnay

CHU Dupuytren, Limoges

Centre Hospitalier Régional d'ORLEANS, Orléans

CH Yves Le Foll, Saint-Brieuc

CHRU de Tours, Tours